A question worth carrying
Sermorelin’s growth findings were about children
The children grew faster. That finding deserves its full sentence.
A folded paper passes across the library ledge.
A signal, rather than growth hormone itself
Sermorelin copies the first 29 building blocks of growth hormone-releasing hormone, or GHRH. The pituitary gland sits beneath the brain. Sermorelin signals it to release growth hormone. The review of its earlier uses explains the distinction.
“Your own hormone” can sound reassuring. But it describes how the drug works, not whether a particular use is safe or helpful. The pituitary still has to be able to respond.
Its only former FDA-approved uses were a test of growth hormone release and treatment of growth failure in children with growth hormone deficiency. It was never approved to treat growth hormone deficiency in adults.
Old approval stays in the past
FDA found the former products were not withdrawn for safety or effectiveness reasons. There is no FDA-approved sermorelin product on sale in the U.S. today. Compounded medicines are not FDA-approved.
What the growth study found
In the study of children with a hormone deficiency, children before puberty grew faster during the first year. Everyone knew the treatment, and there was no comparison group.
That finding concerns growth during a year. It does not establish a particular final adult height, or show that an adult taking sermorelin becomes taller.
A child’s result needs a child’s context
The height FAQ separates the child and adult questions. A paper cannot explain why a particular child is growing slowly. That needs an assessment of the child, rather than a match between a search term and a peptide name.
Adult hopes need adult evidence
A short study in healthy older men found changes in growth hormone and IGF-1, a related growth factor. It did not establish lasting improvements in everyday energy or health.
Older studies reported flushing and injection-site pain. Those findings, mostly from children, cannot supply side-effect rates for adults using compounded products today.
The safety question stays open
In reviews of related drugs, FDA flags possible growth hormone risks, including raised blood sugar, fluid build-up and tumors. Applying that concern to sermorelin is an analogy, not a measured adult risk rate. The same reviews say these drugs cannot work in complete growth hormone deficiency. “Natural” cannot settle those questions.